Search
"A Single Injection" Holds Promise for Curing Epilepsy: Shanghai Makes Major Breakthrough in Cell Drug Research and Development, Leading the World with Dual Approvals from China and the US
2 day ago /
Read about 0 minute
Author：小编
On April 8, UX-GIP001, a novel cell therapy drug independently developed by Shanghai Ucell Biotechnology Co., Ltd., was approved by China's National Medical Products Administration and is set to commence Phase I clinical trials. This drug is the world's first allogeneic cell therapy for epilepsy derived from induced pluripotent stem cells (iPSCs). It also received clinical trial approval from the US FDA last month, becoming the first innovative drug in this field to secure "dual approvals" from both China and the US.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
